Skip to content

Assessment of the impact of a clinical pharmacist compared to standard care in improving quality use of medicines, patient adherence and reducing hospital readmissions in patients diagnosed with acute coronary syndrome

A randomised control trial to evaluate the impact of a clinical pharmacist on optimizing the quality use of medicines according to the Acute Coronary Syndrome (ACS) secondary prevention guidelines and medication adherence following discharge in patients with ACS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2019/039
Enrollment
Unknown
Registered
2019-11-10
Start date
2019-11-12
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Interventions

The study will be conducted at the Medical wards of Teaching hospital Peradeniya. The patients will be randomized into control and intervention groups by block randomization method. There are four s

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Male and female patients above 18 years of age who are diagnosed and managed as ACS by the medical team will be considered as the study population in this study

Exclusion criteria

Exclusion criteria: Patients who refuse to participate Patients who are diagnosed with psychological disorders Patients who are younger than 18 years Patients who are pregnant

Design outcomes

Primary

MeasureTime frame
1) Number of hospital readmissions due to acute coronary syndrome related issues during the study period [At the end of the followup period (six months after discharge)] 2) Changes in medication adherence. (Patients medication adherence will be compared between the time of recruitment and end of study at six months after discharge using a validated tool (Brief Medication Questionnaire) [ ]

Secondary

MeasureTime frame
Number of Drug related problems [ At the end of the followup period (six months after discharge)] Number of adverse drug reactions during the study period [ At the end of the followup period (six months after discharge)] Cost effectiveness of clinical pharmacist intervention [ At the end of the followup period (six months after discharge)]

Countries

Sri Lanka

Contacts

Public ContactN. M. Y. Bagyawantha

Lecturer (Probationary)

bagyawanthanmy@gmail.com0812065792

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026